CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that collaborating investigators from ARIAD, the Howard Hughes Medical Institute, and the Oregon Health and Science University will present data from preclinical studies on AP24534, a novel kinase inhibitor, at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida, December 9 to 12, 2006.
